Infectious Disease February 27, 2024 Baseimmune secures funding for vaccine development By PBR Staff Writer The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of
Drug DiscoveryRegulationOncology February 26, 2024 EMA CHMP provides positive opinion for Janssen’s multiple myeloma therapy By PBR Staff Writer The recommendation for granting Type II variation approval supports the use of cilta-cel for adult patients with RRMM who have received a minimum of one therapy earlier, including
Drug Discovery February 23, 2024 FDA grants fast track status to Artiva’s AlloNK for lupus nephritis By PBR Staff Writer Artiva had previously secured FDA clearance for an investigational new drug application for AlloNK plus rituximab for LN. This marked the first IND clearance for an allogeneic, off-the-shelf
News February 22, 2024 FDA accepts Servier’s NDA review for glioma treatment By PBR Staff Writer Concurrently, the European Medicines Agency (EMA) granted accelerated assessment for the marketing authorization application (MAA) of the same drug. On receipt of approval, vorasidenib would become the sixth
Drug DiscoveryCardiovascular February 21, 2024 IsomAb secures funds to advance peripheral arterial disease treatment By PBR Staff Writer The financing round was spearheaded by Broadview Ventures, with additional support from current investor SCVC and new participant MEIF Proof of Concept & Early Stage Fund. Mercia Ventures
Research & Development February 20, 2024 Everest Medicines to terminate deal with Providence for mRNA platform By PBR Staff Writer This decision grants Everest the full ownership of intellectual property rights and worldwide rights for these products. The latest development is aimed at enhancing Everest’s flexibility in aligning
Drug Discovery February 19, 2024 FDA grants breakthrough therapy status for Otsuka’s IgAN drug By PBR Staff Writer A humanised IgG2 monoclonal antibody, sibeprenlimab acts on the B-cell growth factor dubbed APRIL, a critical player in IgAN’s development and progression. By neutralising APRIL, the drug aims
RegulationOncology February 16, 2024 Japan grants priority review for Astellas’ urothelial cancer regimen By PBR Staff Writer This review could potentially lead to the approval of the first combination treatment offering an alternative to platinum-containing chemotherapy as the first-line treatment for locally advanced or metastatic
Drug Discovery February 15, 2024 Atara submits IND application to FDA for CAR T-cell therapy By PBR Staff Writer ATA3219 utilises allogeneic T cells to act on the CD19 antigen found on B cells, which are implicated in B-cell mediated autoimmune diseases such as systemic lupus erythematosus
Drug DiscoveryOncology February 14, 2024 ProfoundBio secures $112m to advance ADC portfolio for cancer By PBR Staff Writer Ally Bridge Group led the funding round, which saw contributions from healthcare focused and mutual fund institutional investors. New investors comprised Nextech Invest, funds and accounts advised by